Literature DB >> 32973330

Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia/lymphoma.

Kyohei Yamada1, Hiroaki Miyoshi2, Noriaki Yoshida1,3, Joji Shimono1,4, Kensaku Sato1, Kazutaka Nakashima1, Mai Takeuchi1, Fumiko Arakawa1, Naoko Asano1,5, Eriko Yanagida1, Masao Seto1, Koichi Ohshima1.   

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is caused by human T-cell leukemia virus type 1 (HTLV-1). HTLV-1-associated mRNA, including HBZ and tax, is deeply involved in the pathogenesis of ATLL. Using 88 ATLL tissue samples, we performed in situ mRNA analysis of HBZ and tax, and investigated its association with clinicopathological characteristics of ATLL. The median value of HBZ signals (/1000 ATLL cells) was 795.2 (range: 0.4-4013.1) and of tax signals (/1000 ATLL cells) was 5.1 (range: 0.1-891.2). The low-expression HBZ group displayed significant increase in the number of skin lesion (P = 0.0283). The high-expression tax group displayed significant increase in the number of PD-1-positive tumor-infiltrating lymphocytes (P < 0.0001). In addition, we identified patients with very high-expression of tax signals (400 or more signals/1000 ATLL cells). These patients displayed significant reductions in the expression of HLA class I (P = 0.0385) and β2M (P = 0.0124). Moreover, these patients displayed significantly poor overall survival (median survival time [MST] 7.7 months, 95% confidence interval [CI] [4.7-NA]), compared with the survival in patients with less than 400 tax signals (MST 22.6 months, 95% CI [13.7-41.7]) (P = 0.0499). These results suggest that Tax-mediated treatment of ATLL should be performed carefully in the high-expression tax group. More detailed studies could elucidate the clinicopathological significance of HBZ and tax mRNA expressions in ATLL.

Entities:  

Year:  2020        PMID: 32973330     DOI: 10.1038/s41379-020-00654-0

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  43 in total

1.  Long-term study of indolent adult T-cell leukemia-lymphoma.

Authors:  Yumi Takasaki; Masako Iwanaga; Yoshitaka Imaizumi; Masayuki Tawara; Tatsuro Joh; Tomoko Kohno; Yasuaki Yamada; Shimeru Kamihira; Schuichi Ikeda; Yasushi Miyazaki; Masao Tomonaga; Kunihiro Tsukasaki
Journal:  Blood       Date:  2010-03-26       Impact factor: 22.113

Review 2.  Molecular mechanisms of cellular transformation by HTLV-1 Tax.

Authors:  Ralph Grassmann; Mordechai Aboud; Kuan-Teh Jeang
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

3.  The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones.

Authors:  Nicolas A Gillet; Nirav Malani; Anat Melamed; Niall Gormley; Richard Carter; David Bentley; Charles Berry; Frederic D Bushman; Graham P Taylor; Charles R M Bangham
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

4.  Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I.

Authors:  R Iwanaga; K Ohtani; T Hayashi; M Nakamura
Journal:  Oncogene       Date:  2001-04-19       Impact factor: 9.867

Review 5.  Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation.

Authors:  Masao Matsuoka; Kuan-Teh Jeang
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

Review 6.  The HTLV-1 Tax protein: revealing mechanisms of transcriptional activation through histone acetylation and nucleosome disassembly.

Authors:  Jennifer K Nyborg; Dinaida Egan; Neelam Sharma
Journal:  Biochim Biophys Acta       Date:  2009-09-25

7.  Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).

Authors:  M Shimoyama
Journal:  Br J Haematol       Date:  1991-11       Impact factor: 6.998

8.  Tax protein of HTLV-1 interacts with the Rel homology domain of NF-kappa B p65 and c-Rel proteins bound to the NF-kappa B binding site and activates transcription.

Authors:  T Suzuki; H Hirai; M Yoshida
Journal:  Oncogene       Date:  1994-11       Impact factor: 9.867

9.  Treatment and survival among 1594 patients with ATL.

Authors:  Hiroo Katsuya; Kenji Ishitsuka; Atae Utsunomiya; Shuichi Hanada; Tetsuya Eto; Yukiyoshi Moriuchi; Yoshio Saburi; Masaharu Miyahara; Eisaburo Sueoka; Naokuni Uike; Shinichiro Yoshida; Kiyoshi Yamashita; Kunihiro Tsukasaki; Hitoshi Suzushima; Yuju Ohno; Hitoshi Matsuoka; Tatsuro Jo; Masahiro Amano; Ryosuke Hino; Mototsugu Shimokawa; Kazuhiro Kawai; Junji Suzumiya; Kazuo Tamura
Journal:  Blood       Date:  2015-09-11       Impact factor: 22.113

10.  HTLV-1-infected T cells contain a single integrated provirus in natural infection.

Authors:  Lucy B Cook; Aileen G Rowan; Anat Melamed; Graham P Taylor; Charles R M Bangham
Journal:  Blood       Date:  2012-09-06       Impact factor: 22.113

View more
  4 in total

1.  The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation.

Authors:  Kosuke Toyoda; Jun-Ichirou Yasunaga; Ilseung Choi; Youko Suehiro; Naokuni Uike; Jun Okamura; Masao Matsuoka
Journal:  Bone Marrow Transplant       Date:  2021-04-29       Impact factor: 5.174

Review 2.  Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma.

Authors:  Noriaki Yoshida; Kyohei Yamada; Koichi Ohshima
Journal:  Cancer Sci       Date:  2021-02-25       Impact factor: 6.716

3.  Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma.

Authors:  Fumiko Arakawa; Hiroaki Miyoshi; Noriaki Yoshida; Kazutaka Nakashima; Yosaku Watatani; Takuya Furuta; Kyohei Yamada; Mayuko Moritsubo; Mai Takeuchi; Eriko Yanagida; Yasumasa Shimasaki; Kei Kohno; Keisuke Kataoka; Koichi Ohshima
Journal:  Cancer Med       Date:  2021-09-03       Impact factor: 4.452

Review 4.  Pathogenesis of HTLV-1 infection and progression biomarkers: An overview.

Authors:  Carlos Brites; Maria Fernanda Grassi; Juarez Antônio Simões Quaresma; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  Braz J Infect Dis       Date:  2021-07-10       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.